Article Details
Retrieved on: 2024-04-30 16:21:09
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
By later this year, the company expects to be able to produce at least 50% more sellable doses of Zepbound and Mounjaro than it could in 2023.
Article found on: www.biopharmadive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here